Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial

Aim: This multi‐centre, prospective, controlled trial was designed to examine the biological response of the matrix metalloproteinase(MMP) inhibitor subantimicrobial dose doxycycline (SDD) combined with access flap surgery on periodontal wound repair in patients with chronic severe periodontitis. Ma...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical periodontology 2009-02, Vol.36 (2), p.149-156
Main Authors: Gapski, Ricardo, Hasturk, Hatice, Van Dyke, Thomas E., Oringer, Richard J., Wang, Shufang, Braun, Thomas M., Giannobile, William V.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Chronic Periodontitis - drug therapy
Chronic Periodontitis - enzymology
Chronic Periodontitis - surgery
Collagen Type I - analysis
Dentistry
Double-Blind Method
doxycycline
Doxycycline - analogs & derivatives
Doxycycline - therapeutic use
Facial bones, jaws, teeth, parodontium: diseases, semeiology
Female
Gingival Crevicular Fluid - chemistry
Humans
Male
matrix metalloproteinases
Matrix Metalloproteinases - metabolism
Medical sciences
Middle Aged
MMP
Non tumoral diseases
Otorhinolaryngology. Stomatology
Peptides - analysis
periodontal
Pharmacology. Drug treatments
Prospective Studies
Tissue Inhibitor of Metalloproteinases - therapeutic use
wound healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: This multi‐centre, prospective, controlled trial was designed to examine the biological response of the matrix metalloproteinase(MMP) inhibitor subantimicrobial dose doxycycline (SDD) combined with access flap surgery on periodontal wound repair in patients with chronic severe periodontitis. Material and Methods: Seventy subjects were enrolled into a 12‐month, randomized, placebo‐controlled, double‐masked trial to evaluate disease response to 6 months therapy and “wash‐out” of either placebo+surgery or SDD (20 mg b.i.d.)+surgery. Primary outcome measure included clinical attachment levels (CAL) and secondary outcomes included probing depth (PD), bleeding on probing (BOP), as well as gingival crevicular fluid bone marker assessment [collagen telopeptides (ICTP)]. These measurements were taken at baseline through 12 months post‐surgery and drug administration. Results: Patients treated with SDD and surgery demonstrated stronger reductions in PD in surgically‐treated sites of 7 mm as well as gains in CAL (p
ISSN:0303-6979
1600-051X
DOI:10.1111/j.1600-051X.2008.01351.x